Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmascience Appeals Canadian Copaxone 40mg Ruling

Mixed Verdict Involving Teva Sees One Patent Invalidated And Another Upheld

Executive Summary

A mixed verdict in Canadian litigation involving Pharmascience has seen one patent protecting Teva’s Copaxone 40mg upheld and one deemed invalid. Pharmascience plans to appeal.

You may also be interested in...

US Copaxone patents confirmed as invalid

Four patents protecting Teva’s Copaxone (glatiramer acetate) 40mg/ ml thrice-weekly formulation are invalid as obvious, the US Court of Appeals has confirmed in two parallel decisions. The decisions remove the threat of damages against Mylan and Sandoz, which launched glatiramer acetate (GA) 40mg pre-filled syringes ‘at risk’ pending Teva’s appeal (Generics bulletin, 16 February 2018, page 15).

Shortlist Revealed Ahead Of October Awards

Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.

Amgen: Regulatory Reform Must Not Tie The FDA’s Hands On Evaluating Biosimilarity

As the US Food and Drug Administration re-evaluates the need for comparative clinical efficacy studies for biosimilars, Leah Christl – executive director for global biosimilars regulatory affairs and R&D policy at Amgen, and former associate director for therapeutic biologics at the FDA – suggests that any reforms should be careful not to tie the agency’s hands in evaluating biosimilarity.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts